Table 3.

Treatment choice and complications.

	Patient
	1	2	3	4	5	6	7
The severity of the disease	Asymptomatic	Mild	Moderate	Severe	Severe	Critical	Critical
IS adjustment
MMF reduction or interruption	No	No	I	R	I	R	I
FK506 reduction or interruption	No	No	I	R	I	R	I
Treatment
Antivirus therapy	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Arbidol	No	Yes	Yes	Yes	Yes	Yes	Yes
Lopinavir/ritonavir	No	No	Yes	No	No	No	Yes
Chloroquine phosphate	No	No	Yes	No	No	No	No
IVIG/days	No	Yes/7d	Yes/7d	Yes/5d	Yes/3d	Yes/7d	Yes/14d
MP/days	No	No	Yes/10d	Yes/3d	Yes/3d	No	Yes/18d
Other complications and support
Septic shock	No	No	No	No	No	No	No
ICU admission	No	No	No	No	No	Yes	Yes
AKI	No	No	Yes	No	No	Yes	Yes
Rejection	No	No	Yes	No	No	No	Yes
Acute cardiac injury	No	No	No	No	No	Yes	Yes
ARDS	No	No	No	Yes	Yes	Yes	Yes
Life support
Initiation of invasive ventilation	No	No	No	No	No	No	Yes
Initiation of noninvasive ventilation	No	No	No	No	No	Yes	Yes
Initiation of renal replacement therapy	No	No	No	No	No	Yes	Yes
Outcome	Discharge	Discharge	Discharge	Discharge	Discharge	Discharge	Death

Note: IS = immunosuppressant; MPA = mycophenolic acid; FK506 = tacrolimus; IVIG = intravenous immunoglobulin; MP = methylprednisolone; ICU = intensive care unit, AKI = acute kidney injury; ARDS = acute respiratory distress syndrome.